iPS Cell Selection via Exogenous Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for establishing induced pluripotent stem (iPS) cells often result in cells with high expression of exogenous nuclear reprogramming genes, which can be unsafe for clinical applications due to potential gene repression issues, necessitating a method to select iPS cells with repressed transgene expression.
Innovation Solution
A method involving quantitative PCR to measure the expression levels of exogenous nuclear reprogramming genes and their corresponding endogenous genes in iPS cells, selecting cells with expression levels or ratios below control values, using specific primer sets to assess the expression levels of genes like Oct3/4, Sox2, and c-Myc, to identify cells with repressed transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If virus vectors such as retroviruses and lentiviruses are used to introduce exogenous nuclear reprogramming genes, then gene transfer efficiency is improved, but the risk of chromosomal integration and potential harmful effects increases
Solution Approach 1:
The patent extracts and eliminates the harmful chromosomal integration risk by selecting iPS cells that have lost the exogenous nuclear reprogramming genes through spontaneous deletion or silencing. This allows the use of efficient virus vectors while mitigating the harmful integration effect through rigorous selection criteria based on gene expression levels and chromosomal analysis.
2Productivity
If exogenous nuclear reprogramming genes are introduced to establish iPS cells, then reprogramming capability is improved, but transgene expression repression occurs which affects safety for clinical application
Solution Approach 1:
The patent applies preliminary action by establishing iPS cells with exogenous nuclear reprogramming genes first, then performing preliminary selection and screening to identify cells that have spontaneously repressed transgene expression. This preliminary selection process ensures that only safe cells with appropriate gene repression are used for clinical applications, maintaining reprogramming capability while ensuring safety.
Solution Approach 2:
The patent implements feedback mechanisms through multiple assessment methods including quantitative PCR to measure exogenous gene expression levels, analysis of chromosomal integration status, and evaluation of cell morphology and differentiation potential. This feedback loop allows continuous monitoring and selection of cells that meet safety criteria for clinical application.
3Reliability
If a method is developed to select iPS cells with repressed transgene expression, then safety for clinical application is improved, but the complexity of the selection process increases
Solution Approach 1:
The patent segments the complex selection process into multiple independent assessment steps: (1) quantitative PCR analysis to measure exogenous gene expression levels, (2) chromosomal analysis to detect integration status, (3) morphological assessment of iPS cell colonies, and (4) differentiation potential evaluation. This segmentation allows systematic evaluation of multiple criteria without overwhelming complexity, making the selection process more manageable and reproducible.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient selection of iPS cells with repressed transgene expression, enhancing their safety for clinical applications by ensuring low expression levels of critical genes such as Oct3/4, Sox2, and c-Myc, thereby improving their suitability for regenerative medicine.
Implementation Method 1
primer sets for PCR for measuring the sum of the expression levels of the exogenous nuclear reprogramming gene(s) and the corresponding endogenous gene(s), and primer sets for PCR for measuring only the expression level of the exogenous nuclear reprogramming gene(s)
Data Source
AI summary
The present invention relates to a method for selecting induced pluripotent stem (iPS) cells. More particularly, the present invention provides: a method for selecting an iPS cell, comprising the steps of: (1a) measuring the expression level of an exogenous nuclear reprogramming gene(s) in a test iPS cell; and (2a) selecting an iPS cell in which the expression level(s) of an exogenous nuclear reprogramming gene(s) is/are less than or equal to the expression level(s) in control iPS cells; and a method for selecting an iPS cell, comprising the steps of: (1b) measuring the expression level of an exogenous nuclear reprogramming gene(s) and the sum the expression levels of the exogenous nuclear reprogramming gene(s) and the corresponding endogenous gene iPS cell; and (2b) selecting an iPS cell in which the ratio of the expression level of an exogenous nuclear reprogramming gene(s) relative to the sum of the expression levels of the exogenous transgene(s) and the corresponding endogenous gene(s) is less than 1 to the ratio in the control iPS cell.